Effects of interleukin-1β and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study

doi:10.1016/S0006-8993(97)00312-0

Brain Research

Volume 761, Issue 2, 4 July 1997, Pages 225-235

https://doi.org/10.1016/S0006-8993(97)00312-0 Get rights and content

Abstract

The effects of systemically administered interleukin-1β (1.0 μg) on in vivo variations of monoamines was assessed in several brain regions. Administration of the cytokine provoked a modest increase of extracellular 5-HIAA and HVA from the nucleus accumbens, and 5-HIAA from the hippocampus. Following mild neurogenic stressor (application of a series of air puffs), a still greater increase of accumbal 5-HIAA and HVA was evident, a transient increase of hippocampal 5-HT was noted and the 5-HIAA increases were augmented. Additionally, while the air puff stress was without effect on DOPAC and HVA in the prefrontal cortex of saline treated rats, a significant rise of these metabolites was apparent in rats treated with the cytokine. It appears that interleukin-1 administration may have effects on forebrain monoamines, and also results in greater neuronal reactivity to mild neurogenic stressors. This study reveals that although effects of neurogenic stressors (air puffs) and cytokine (somatic stressor) may share some similarities (e.g., HPA activation), the pattern of central neurochemical changes elicited by the cytokine could be distinguished from that induced by a more neurogenic stressor (air puffs), and that these effects showed selective synergism. These data also lend support to the contention that neurogenic stressors may have a much greater impact on central neurotransmission under conditions of immune activation.

References (64)

W.A. Banks et al.
Bidirectional transport of interleukin-1 alpha across the blood-brain barrier
Brain Res. Bull.
(1989)
F. Berkenbosch et al.
Neuroendocrine and immunological mechanisms in stress-induced immunomodulation
J. Steroid Biochem. Mol. Biol.
(1991)
H.O. Besedovsky et al.
Physiological implications of the immune-neuro-endocrine network
S.L. Carlson et al.
Alterations of monoamines in specific central autonomic nuclei following immunization in mice
Brain Behav. Immun.
(1987)
M.F. Dallman et al.
Regulation of the hypothalamo-pituitary adrenal axis during stress: feedback, facilitation and feeding
Semin. Neurosci.
(1994)
R. Dantzer et al.
Stress and immunity: an integrated view of relationships between the brain and the immune system
Life Sci.
(1989)
J.F.W. Deakin et al.
Microdialysis studies with 5-HT reuptake inhibitors
Reply. Trends Pharmacol. Sci.
(1993)
A.Y. Deutch et al.
Footshock and conditioned stress increase 3,4-dihydroxyphenylacetic acid (DOPAC) in the ventral tegmental area but not substantia nigra
Brain Res.
(1985)
A.J. Dunn
Systemic interleukin-1 administration stimulates hypothalamic norepinephrine metabolism paralleling the increased plasma corticosterone
Life Sci.
(1988)
A.J. Dunn et al.
Virus infection as a stressor: influenza virus elevates plasma concentrations of corticosterone, and brain concentrations of MHPG and tryptophan
Physiol. Behav.
(1989)

A.J. Dunn et al.

Effects of Newcastle disease virus administration to mice on the metabolism of cerebral biogenic amines, plasma corticosterone, and lymphocyte proliferation

Brain Behav. Immun.

(1987)

A.M. Gardier et al.

Effects of a primary immune response to T-cell dependent antigen on serotonin metabolism in frontal cortex: in vivo microdialysis study in freely moving Fischer 344 rat

Brain Res.

(1994)

S.J. Hopkins et al.

Cytokines and the nervous system I. Expression and recognition

Trends Neurosci.

(1995)

A. Kabiersch et al.

Interleukin-1 induces changes in norepinephrine metabolism in the rat brain

Brain Behav. Immun.

(1988)

G. Katsuura et al.

Identification of a high-affinity receptor for interleukin-1 beta in rat brain

Biochem. Biophys. Res. Commun.

(1988)

S. Lacosta et al.

Time-dependent in vivo mesolimbic dopamine variations following antigenic challenge

Brain Res.

(1994)

S.F. Maier et al.

Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock

Brain Res.

(1995)

M.I. Masana et al.

Indomethacin prevents increased catecholamine turnover in rat brain following systemic endotoxin challenge

Prog. Neuro-Psychopharmacol. Biol. Psychiat.

(1990)

I.N. Mefford et al.

Increased biogenic amine release in mouse hypothalamus following immunological challenge: antagonism by indomethacin

J. Neuroimmunol.

(1990)

P.S. Mohankumar et al.

Interleukin-1β increases 5-hydroxyindoleacetic acid release in the hypothalamus in vivo

Brain Res. Bull.

(1993)

P.S. Mohankumar et al.

Interleukin-1 stimulates the release of dopamine and dihydroxyphenylacetic acid from hypothalamus in vivo

Life Sci.

(1991)

G. Nistico et al.

Is interleukin 2 a neuromodulator in the brain?

Trends Neurosci.

(1991)

C.R. Plata-Salaman

Immunoregulators in the nervous system

Neurosci. Biobehav. Rev.

(1991)

N.J. Rothwell et al.

Cytokines and the nervous system II. Actions and mechanisms of action

Trends Neurosci.

(1995)

N. Shanks et al.

Alterations of central catecholamines associated with immune responding in adult and aged mice

Brain Res.

(1994)

L.R. Watkins et al.

Cytokine-to-brain communication: a review and analysis of alternative mechanisms

Life Sci.

(1995)

B.H.C. Westerink

Brain microdialysis and its application for the study of animal behaviour

Behav. Brain Res.

(1995)

T. Zetterstrom et al.

In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs: implications for the origin of extracellular DOPAC

Eur. J. Pharmacol.

(1988)

E.D. Abercrombie et al.

Differential effects of stress on in vivo dopamine release in striatum, nuclues accumbens, and medial frontal cortex

J. Neurochem.

(1989)

H. Anisman et al.

Multi-system regulation of performance deficits induced by stressors: an animal model of depression

H. Anisman et al.

The impact of stressors on immune and central neurotransmitter activity: bidirectional communication

Rev. Neurosci.

(1993)

B.M. Araujo et al.

Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: interaction with the cholinergic system

Brain Res.

(1989)

Cited by (116)

Neuro-immune crosstalk in depressive symptoms of multiple sclerosis
2023, Neurobiology of Disease
Depressive disorders can occur in up to 50% of people with multiple sclerosis in their lifetime. If left untreated, comorbid major depressive disorders may not spontaneously remit and is associated with an increased morbidity and mortality. Conversely, epidemiological evidence supports increased psychiatric visit as a significant prodromal event prior to diagnosis of MS. Are there common molecular pathways that contribute to the co-development of MS and psychiatric illnesses? We discuss immune cells that are dysregulated in MS and how such dysregulation can induce or protect against depressive symptoms. This is not meant to be a comprehensive review of all molecular pathways but rather a framework to guide future investigations of immune responses in depressed versus euthymic people with MS. Currently, there is weak evidence supporting the use of antidepressant medication in comorbid MS patients. It is our hope that by better understanding the neuroimmune crosstalk in the context of depression in MS, we can enhance the potential for future therapeutic options.
Clinical trials of anti-inflammatory treatments of major depression
2018, Inflammation and Immunity in Depression: Basic Science and Clinical Applications
A mounting body of literature indicates a dysregulated immune system as the underlying pathogenetic mechanism of major depression (MD), at least in a subgroup of patients. Stress, particularly in early childhood, contributes to this pro-inflammatory state, and the activated inflammatory state is known to impact brain development and function. The pro-inflammatory state is a target of experimental therapeutic approaches, for example, add-on treatment with a cyclooxygenase-2 (COX-2) inhibitor. COX-2 inhibitors downregulate increased inflammatory markers and have therefore been studied as a potential treatment for MD. The outcome of these studies varies, depending on several factors; meta-analyses, however, show a benefit of COX-2 inhibitors in MD. Possible immune markers that may predict the response are discussed, including neuroactive metabolites of the tryptophan-kynurenine system. Moreover, additional immunotherapeutic approaches are reported, such as antibodies against interleukin-6 (IL-6), other targets of the IL-6 receptor complex, or tumor necrosis factor-alpha. In most of the trials, the immunotherapeutic agent was given as an add-on to an established antidepressant. However, to show a statistically significant effect, the anti-inflammatory compound needs to have a large additional effect. Additional important factors may include duration of disease, setting (inpatient vs outpatient), disease severity, and study design (monocenter vs multicenter). Anti-inflammatory treatment has an additional benefit in certain types of patients, but further intense research is required to identify these patients. From a scientific perspective, studies of monotherapy with anti-inflammatory agents would be required, although ethical concerns exist. Future research has to consider possible biomarkers, monocentric versus multicentric study design, and additional clinical parameters.
Sex differences in the neuro-immune consequences of stress: Focus on depression and anxiety
2018, Brain, Behavior, and Immunity
Citation Excerpt :
Furthermore, the expression and regulation of GR, as well as interaction of sex steroids with GR, are sexually dimorphic (Bourke et al., 2012, 2013; Bourke and Neigh, 2011), and may lead to differential onset, magnitude, and resolution of endocrine responses in males and females during stressor exposure. Inflammatory processes in the brain influence many aspects of normal and pathological physiology in the brain such as alterations in synaptic (Pribiag and Stellwagen, 2014) and neuronal plasticity (Kubera et al., 2011), neurotransmission (Haroon et al., 2016; Merali et al., 1997), and related behavioral outcomes (Howerton et al., 2014). Males and females display distinct vulnerabilities to different types of inflammatory dysregulation which suggests underlying biological differences.
Women appear to be more vulnerable to the depressogenic effects of inflammation than men. Chronic stress, one of the most pertinent risk factors of depression and anxiety, is known to induce behavioral and affective-like deficits via neuroimmune alterations including activation of the brain’s immune cells, pro-inflammatory cytokine expression, and subsequent changes in neurotransmission and synaptic plasticity within stress-related neural circuitry. Despite well-established sexual dimorphisms in the stress response, immunity, and prevalence of stress-linked psychiatric illnesses, much of current research investigating the neuroimmune impact of stress remains exclusively focused on male subjects. We summarize and evaluate here the available data regarding sex differences in the neuro-immune consequences of stress, and some of the physiological factors contributing to these differences. Furthermore, we discuss the extent to which sex differences in stress-related neuroinflammation can account for the overall female bias in stress-linked psychiatric disorders including major depressive disorder and anxiety disorders. The currently available evidence from rodent studies does not unequivocally support the peripheral inflammatory changes seen in women following stress. Replication of many recent findings in stress-related neuroinflammation in female subjects is necessary in order to build a framework in which we can assess the extent to which sex differences in stress-related inflammation contribute to the overall female bias in stress-related affective disorders.
Anti-Inflammatory and Immune-Modulatory Therapeutic Approaches in Major Depression
2016, Systems Neuroscience in Depression
High levels of several proinflammatory components of the immune system such as interleukin-6 (IL-6), C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), or neopterin in patients suffering from major depression (MD) point to the involvement of an inflammatory process in the pathophysiology of MD. Direct and indirect effects of cytokines on the neurotransmitter storage and release—mediated by microglia cells and astrocytes—are discussed. The tryptophan/kynurenine metabolism mediates the activity of the immune system and the serotonergic and glutamatergic neurotransmissions. The enzyme indoleamine 2,3-dioxygenase (IDO)—a key enzyme of this metabolism in the central nervous system (CNS)—is driven by pro- and anti-inflammatory cytokines and degrades serotonin. Moreover, neuroactive kynurenines such as kynurenic acid and quinolinic acid act on the glutamatergic neurotransmission as N-methyl-d-aspartate (NMDA)—antagonists and agonists, respectively. Alterations of the serotonergic, noradrenergic, and glutamatergic neurotransmissions are associated with low-level neuroinflammation. Epidemiological and clinical studies point to a key role for inflammation as risk factor for MD. A large-scale epidemiological study in MD clearly demonstrates that severe infections and autoimmune disorders are lifetime risk factors for MD. Neuroinflammation in the prefrontal cortex, the nucleus accumbens, and the insula has been shown in MD by in vivo positron emission tomography. Further support comes from the therapeutic benefit of anti-inflammatory compounds in MD such as the cyclo-oxygenase-2 (COX-2) inhibitors or TNF-α antagonists. On the other hand, antidepressants have anti-inflammatory and immunomodulatory intrinsic effects. The beneficial effect of both, COX-2 inhibitors alone and of the approach of anti-inflammatory treatment in MD, has been shown in meta-analyses in the meantime.
Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response
2015, Neuroscience and Biobehavioral Reviews
The role of serotonin in depression and antidepressant treatment remains unresolved despite decades of research. In this paper, we make three major claims. First, serotonin transmission is elevated in multiple depressive phenotypes, including melancholia, a subtype associated with sustained cognition. The primary challenge to this first claim is that the direct pharmacological effect of most symptom-reducing medications, such as the selective serotonin reuptake inhibitors (SSRIs), is to increase synaptic serotonin. The second claim, which is crucial to resolving this paradox, is that the serotonergic system evolved to regulate energy. By increasing extracellular serotonin, SSRIs disrupt energy homeostasis and often worsen symptoms during acute treatment. Our third claim is that symptom reduction is not achieved by the direct pharmacological properties of SSRIs, but by the brain's compensatory responses that attempt to restore energy homeostasis. These responses take several weeks to develop, which explains why SSRIs have a therapeutic delay. We demonstrate the utility of our claims by examining what happens in animal models of melancholia and during acute and chronic SSRI treatment.
Integrating the monoamine, neurotrophin and cytokine hypotheses of depression - A central role for the serotonin transporter?
2015, Pharmacology and Therapeutics
Monoamine, in particular serotonergic neurotransmission has long been recognized as an important factor in the aetiology of depression. The serotonin transporter (SERT) is the primary regulator of serotonin levels in the brain and a key target for widely used antidepressant drugs, such as selective serotonin reuptake inhibitors (SSRIs). In realising the limitations of current antidepressant therapy, depression research has branched out to encompass other areas such as synaptic plasticity, neurogenesis and brain structural remodelling as factors which influence mood and behaviour. More recently, the immune system has been implicated in the development of depression and various intriguing observations have inspired the cytokine hypothesis of depression. Over the past two decades evidence of in vitro and in vivo regulation of SERT function by pro-inflammatory cytokines as well as by mechanisms of synaptic plasticity has been accumulating, offering a mechanistic link between the monoamine, neurotrophin and cytokine theories of depression. This review will focus firstly on the interconnected roles of serotonin and neurotrophins in depression and antidepressant therapy, secondly on the impact of the immune system on serotonin transporter regulation and neurotrophin signalling and finally we propose a model of reciprocal regulation of serotonin and neurotrophin signalling in the context of inflammation-induced depression.

View all citing articles on Scopus

View full text

Research reportEffects of interleukin-1β and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study

Abstract

Brain Res. Bull.

J. Steroid Biochem. Mol. Biol.

Brain Behav. Immun.

Semin. Neurosci.

Life Sci.

Reply. Trends Pharmacol. Sci.

Brain Res.

Life Sci.

Physiol. Behav.

Brain Behav. Immun.

Brain Res.

Trends Neurosci.

Brain Behav. Immun.

Biochem. Biophys. Res. Commun.

Brain Res.

Brain Res.

Prog. Neuro-Psychopharmacol. Biol. Psychiat.

J. Neuroimmunol.

Brain Res. Bull.

Life Sci.

Trends Neurosci.

Neurosci. Biobehav. Rev.

Trends Neurosci.

Brain Res.

Life Sci.

Behav. Brain Res.

Eur. J. Pharmacol.

Differential effects of stress on in vivo dopamine release in striatum, nuclues accumbens, and medial frontal cortex

J. Neurochem.

Multi-system regulation of performance deficits induced by stressors: an animal model of depression

The impact of stressors on immune and central neurotransmitter activity: bidirectional communication

Rev. Neurosci.

Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: interaction with the cholinergic system

Brain Res.

Research report
Effects of interleukin-1β and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study